A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatment through prior participation in a Pfizer-sponsored clinical trial. Data collection and participant visits will be based on standard of care.
Hemophilia A, Hemophilia B
A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatment through prior participation in a Pfizer-sponsored clinical trial. Data collection and participant visits will be based on standard of care.
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
-
UC Davis Health, Sacramento, California, United States, 95816
UC Davis Ambulatory Care Clinic, Sacramento, California, United States, 95817
UC Davis Hemophilia Treatment Center, Sacramento, California, United States, 95817
UC Davis Medical Center, Sacramento, California, United States, 95817
UCSF Outpatient Hematology Clinic, San Francisco, California, United States, 94143
USF Health Morsani Center For Advanced Healthcare, Tampa, Florida, United States, 33612
Mississippi Center For Advanced Medicine, Madison, Mississippi, United States, 39110
The Childrens Hospital of Philadelphia Division of Hematology, Philadelphia, Pennsylvania, United States, 19104
Washington Institute for Coagulation, Seattle, Washington, United States, 98101
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
MALE
No
Pfizer,
Pfizer CT.gov Call Center, STUDY_DIRECTOR, Pfizer
2039-09-03